← Evidence map

ArticleCardiology and therapy2024

A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".

Sepideh AttalPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)". | OpenQuestion